Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces experimental osteoarthritis and nociception in rats

Z. H. Wen, C. C. Tang, Y. C. Chang, S. Y. Huang, C. H. Chen, S. C. Wu, S. P. Hsieh, C. S. Hsieh, K. Y. Wang, S. Y. Lin, H. L. Lee, C. H. Lee, H. C. Kuo, W. F. Chen, Y. H. Jean

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: To study the effect of intra-articular injection of meloxicam (Mobic) on the development of osteoarthritis (OA) in rats and examine concomitant changes in nociceptive behavior and the expression of mitogen-activated protein kinases (MAPKs) in articular cartilage chondrocytes. Methods: OA was induced in Wistar rats by right anterior cruciate ligament transection (ACLT); the left knee was not treated. The OA+meloxicam (1.0mg) group was injected intra-articularly in the ACLT knee with 1.0mg of meloxicam once a week for 5 consecutive weeks starting 5 weeks after ACLT. The OA+meloxicam (0.25mg) group was treated similarly with 0.25mg meloxicam. The sham group underwent arthrotomy only and received vehicle of 0.1mL sterile 0.9% saline injections, whereas the naive rats in meloxicam-only groups were treated similarly with 1.0- and 0.25-mg meloxicam. Nociception was measured as secondary mechanical allodynia and hind paw weight-bearing distribution at before (pre-) and 5, 10, 15, and 20 weeks post-ACLT. Histopathology of the cartilage and synovia was examined 20 weeks after ACLT. Immunohistochemical analysis was performed to examine the effect of meloxicam on MAPKs (p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK)) expression in the articular cartilage chondrocytes. Results: OA rats receiving intra-articular meloxicam treatment showed significantly less cartilage degeneration and synovitis than saline-treated controls. Nociception were improved in the OA+meloxicam groups compared with the OA group. Moreover, meloxicam attenuated p38 and JNK but enhanced ERK expression in OA-affected cartilage. Conclusions: Intra-articular injection of meloxicam (1) attenuates the development of OA, (2) concomitantly reduces nociception, and (3) modulates chondrocyte metabolism, possibly through inhibition of cellular p38 and JNK, but enhances ERK expression.

Original languageEnglish
Pages (from-to)1976-1986
Number of pages11
JournalOsteoarthritis and Cartilage
Volume21
Issue number12
DOIs
Publication statusPublished - Dec 2013

Fingerprint

meloxicam
Intra-Articular Injections
Nociception
Cyclooxygenase 2 Inhibitors
Ligaments
Cartilage
Osteoarthritis
Rats
Anterior Cruciate Ligament
Bearings (structural)
Proteins
JNK Mitogen-Activated Protein Kinases
Enzyme inhibition
Extracellular Signal-Regulated MAP Kinases
Chondrocytes
Metabolism
Articular Cartilage
Prostaglandin-Endoperoxide Synthases
Knee

Keywords

  • Anterior cruciate ligament
  • MAPK
  • Meloxicam (Mobic)
  • Nociception
  • Osteoarthritis

ASJC Scopus subject areas

  • Biomedical Engineering
  • Orthopedics and Sports Medicine
  • Rheumatology

Cite this

Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces experimental osteoarthritis and nociception in rats. / Wen, Z. H.; Tang, C. C.; Chang, Y. C.; Huang, S. Y.; Chen, C. H.; Wu, S. C.; Hsieh, S. P.; Hsieh, C. S.; Wang, K. Y.; Lin, S. Y.; Lee, H. L.; Lee, C. H.; Kuo, H. C.; Chen, W. F.; Jean, Y. H.

In: Osteoarthritis and Cartilage, Vol. 21, No. 12, 12.2013, p. 1976-1986.

Research output: Contribution to journalArticle

Wen, ZH, Tang, CC, Chang, YC, Huang, SY, Chen, CH, Wu, SC, Hsieh, SP, Hsieh, CS, Wang, KY, Lin, SY, Lee, HL, Lee, CH, Kuo, HC, Chen, WF & Jean, YH 2013, 'Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces experimental osteoarthritis and nociception in rats', Osteoarthritis and Cartilage, vol. 21, no. 12, pp. 1976-1986. https://doi.org/10.1016/j.joca.2013.09.005
Wen, Z. H. ; Tang, C. C. ; Chang, Y. C. ; Huang, S. Y. ; Chen, C. H. ; Wu, S. C. ; Hsieh, S. P. ; Hsieh, C. S. ; Wang, K. Y. ; Lin, S. Y. ; Lee, H. L. ; Lee, C. H. ; Kuo, H. C. ; Chen, W. F. ; Jean, Y. H. / Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces experimental osteoarthritis and nociception in rats. In: Osteoarthritis and Cartilage. 2013 ; Vol. 21, No. 12. pp. 1976-1986.
@article{af5c7fab0b7f4ebf933079b599caf576,
title = "Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces experimental osteoarthritis and nociception in rats",
abstract = "Objective: To study the effect of intra-articular injection of meloxicam (Mobic) on the development of osteoarthritis (OA) in rats and examine concomitant changes in nociceptive behavior and the expression of mitogen-activated protein kinases (MAPKs) in articular cartilage chondrocytes. Methods: OA was induced in Wistar rats by right anterior cruciate ligament transection (ACLT); the left knee was not treated. The OA+meloxicam (1.0mg) group was injected intra-articularly in the ACLT knee with 1.0mg of meloxicam once a week for 5 consecutive weeks starting 5 weeks after ACLT. The OA+meloxicam (0.25mg) group was treated similarly with 0.25mg meloxicam. The sham group underwent arthrotomy only and received vehicle of 0.1mL sterile 0.9{\%} saline injections, whereas the naive rats in meloxicam-only groups were treated similarly with 1.0- and 0.25-mg meloxicam. Nociception was measured as secondary mechanical allodynia and hind paw weight-bearing distribution at before (pre-) and 5, 10, 15, and 20 weeks post-ACLT. Histopathology of the cartilage and synovia was examined 20 weeks after ACLT. Immunohistochemical analysis was performed to examine the effect of meloxicam on MAPKs (p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK)) expression in the articular cartilage chondrocytes. Results: OA rats receiving intra-articular meloxicam treatment showed significantly less cartilage degeneration and synovitis than saline-treated controls. Nociception were improved in the OA+meloxicam groups compared with the OA group. Moreover, meloxicam attenuated p38 and JNK but enhanced ERK expression in OA-affected cartilage. Conclusions: Intra-articular injection of meloxicam (1) attenuates the development of OA, (2) concomitantly reduces nociception, and (3) modulates chondrocyte metabolism, possibly through inhibition of cellular p38 and JNK, but enhances ERK expression.",
keywords = "Anterior cruciate ligament, MAPK, Meloxicam (Mobic), Nociception, Osteoarthritis",
author = "Wen, {Z. H.} and Tang, {C. C.} and Chang, {Y. C.} and Huang, {S. Y.} and Chen, {C. H.} and Wu, {S. C.} and Hsieh, {S. P.} and Hsieh, {C. S.} and Wang, {K. Y.} and Lin, {S. Y.} and Lee, {H. L.} and Lee, {C. H.} and Kuo, {H. C.} and Chen, {W. F.} and Jean, {Y. H.}",
year = "2013",
month = "12",
doi = "10.1016/j.joca.2013.09.005",
language = "English",
volume = "21",
pages = "1976--1986",
journal = "Osteoarthritis and Cartilage",
issn = "1063-4584",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces experimental osteoarthritis and nociception in rats

AU - Wen, Z. H.

AU - Tang, C. C.

AU - Chang, Y. C.

AU - Huang, S. Y.

AU - Chen, C. H.

AU - Wu, S. C.

AU - Hsieh, S. P.

AU - Hsieh, C. S.

AU - Wang, K. Y.

AU - Lin, S. Y.

AU - Lee, H. L.

AU - Lee, C. H.

AU - Kuo, H. C.

AU - Chen, W. F.

AU - Jean, Y. H.

PY - 2013/12

Y1 - 2013/12

N2 - Objective: To study the effect of intra-articular injection of meloxicam (Mobic) on the development of osteoarthritis (OA) in rats and examine concomitant changes in nociceptive behavior and the expression of mitogen-activated protein kinases (MAPKs) in articular cartilage chondrocytes. Methods: OA was induced in Wistar rats by right anterior cruciate ligament transection (ACLT); the left knee was not treated. The OA+meloxicam (1.0mg) group was injected intra-articularly in the ACLT knee with 1.0mg of meloxicam once a week for 5 consecutive weeks starting 5 weeks after ACLT. The OA+meloxicam (0.25mg) group was treated similarly with 0.25mg meloxicam. The sham group underwent arthrotomy only and received vehicle of 0.1mL sterile 0.9% saline injections, whereas the naive rats in meloxicam-only groups were treated similarly with 1.0- and 0.25-mg meloxicam. Nociception was measured as secondary mechanical allodynia and hind paw weight-bearing distribution at before (pre-) and 5, 10, 15, and 20 weeks post-ACLT. Histopathology of the cartilage and synovia was examined 20 weeks after ACLT. Immunohistochemical analysis was performed to examine the effect of meloxicam on MAPKs (p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK)) expression in the articular cartilage chondrocytes. Results: OA rats receiving intra-articular meloxicam treatment showed significantly less cartilage degeneration and synovitis than saline-treated controls. Nociception were improved in the OA+meloxicam groups compared with the OA group. Moreover, meloxicam attenuated p38 and JNK but enhanced ERK expression in OA-affected cartilage. Conclusions: Intra-articular injection of meloxicam (1) attenuates the development of OA, (2) concomitantly reduces nociception, and (3) modulates chondrocyte metabolism, possibly through inhibition of cellular p38 and JNK, but enhances ERK expression.

AB - Objective: To study the effect of intra-articular injection of meloxicam (Mobic) on the development of osteoarthritis (OA) in rats and examine concomitant changes in nociceptive behavior and the expression of mitogen-activated protein kinases (MAPKs) in articular cartilage chondrocytes. Methods: OA was induced in Wistar rats by right anterior cruciate ligament transection (ACLT); the left knee was not treated. The OA+meloxicam (1.0mg) group was injected intra-articularly in the ACLT knee with 1.0mg of meloxicam once a week for 5 consecutive weeks starting 5 weeks after ACLT. The OA+meloxicam (0.25mg) group was treated similarly with 0.25mg meloxicam. The sham group underwent arthrotomy only and received vehicle of 0.1mL sterile 0.9% saline injections, whereas the naive rats in meloxicam-only groups were treated similarly with 1.0- and 0.25-mg meloxicam. Nociception was measured as secondary mechanical allodynia and hind paw weight-bearing distribution at before (pre-) and 5, 10, 15, and 20 weeks post-ACLT. Histopathology of the cartilage and synovia was examined 20 weeks after ACLT. Immunohistochemical analysis was performed to examine the effect of meloxicam on MAPKs (p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK)) expression in the articular cartilage chondrocytes. Results: OA rats receiving intra-articular meloxicam treatment showed significantly less cartilage degeneration and synovitis than saline-treated controls. Nociception were improved in the OA+meloxicam groups compared with the OA group. Moreover, meloxicam attenuated p38 and JNK but enhanced ERK expression in OA-affected cartilage. Conclusions: Intra-articular injection of meloxicam (1) attenuates the development of OA, (2) concomitantly reduces nociception, and (3) modulates chondrocyte metabolism, possibly through inhibition of cellular p38 and JNK, but enhances ERK expression.

KW - Anterior cruciate ligament

KW - MAPK

KW - Meloxicam (Mobic)

KW - Nociception

KW - Osteoarthritis

UR - http://www.scopus.com/inward/record.url?scp=84888861909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888861909&partnerID=8YFLogxK

U2 - 10.1016/j.joca.2013.09.005

DO - 10.1016/j.joca.2013.09.005

M3 - Article

C2 - 24084190

AN - SCOPUS:84888861909

VL - 21

SP - 1976

EP - 1986

JO - Osteoarthritis and Cartilage

JF - Osteoarthritis and Cartilage

SN - 1063-4584

IS - 12

ER -